- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05574361
Continued Access Study to Evaluate Performance of the Organ Recovery Systems _LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™_CA) (PILOT™_CA)
November 2, 2023 updated by: Organ Recovery Systems, Inc.
A Prospective Multi-Center Continued Access Protocol for the Use of the LifePort® Liver Transporter (LLT) System With Vasosol® in Orthotopic Liver Transplants (PILOT™_CA: Perfusion to Improve Liver Outcomes in Transplantation_ Continued Access Arm)
To provide continued access for the LLT system to provide additional safety data in support of the PILOT pivotal efficacy and safety trial
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To provide continued access for the LLT System with Vasosol® for the preservation of whole explanted livers, thereby providing additional safety data in support of the PILOT pivotal efficacy and safety trial
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stan Harris
- Phone Number: 847-824-2600
- Email: sharris@organ-recovery.com
Study Contact Backup
- Name: Carrie Lindower
- Phone Number: 847-824-2600
- Email: clindower@organ-recovery.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern Memorial Hospital
-
Contact:
- Daniel Borja-Cacho, MD
-
Chicago, Illinois, United States, 60637
- Not yet recruiting
- University of Chicago Medical Center
-
Contact:
- John Fung, MD
-
-
New Jersey
-
Newark, New Jersey, United States, 07101
- Recruiting
- Rutgers New Jersey Medical School
-
Contact:
- James V. Guarrera, MD
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Not yet recruiting
- University of Cincinnati Medical Center
-
Contact:
- Shimul Shah, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
- ≥18 years of age.
- Active on the United Network for Organ Sharing (UNOS) waiting list for liver transplantation.
- De novo liver transplant recipient.
- Written informed consent required.
Exclusion Criteria:
- Subject is a multi-organ transplant recipient.
- Subject is antibodies blood group (ABO) liver incompatible.
- Subject has severe systemic infection.
- Subject is Human Immunodeficiency Virus (HIV) positive.
- Subject has acute/fulminant liver failure.
- Subject is pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypothermic Machine Perfusion
Hypothermic Machine Perfusion with Organ Recovery Systems LifePort Liver Transporter system
|
Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early Allograft Dysfunction (EAD)
Time Frame: 7 days
|
EAD defined as total bilirubin ≥ 10 mg/dL or International Normalized Ratio (INR) ≥ 1.6 or Aspartate Aminotransferase (AST) >2000IU/L or Alanine Aminotransferase (ALT) > 2000 IU/L
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Stan Harris, Organ Recovery Systems
- Study Chair: Matthew Copithorne, Organ Recovery Systems
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 19, 2022
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
October 6, 2022
First Submitted That Met QC Criteria
October 6, 2022
First Posted (Actual)
October 10, 2022
Study Record Updates
Last Update Posted (Estimated)
November 3, 2023
Last Update Submitted That Met QC Criteria
November 2, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 2020-US-02-ORS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Rennes University HospitalCompletedLiver Transplantation | Kidney TransplantationFrance
Clinical Trials on Hypothermic Machine Perfusion
-
Azienda Ospedaliero, Universitaria PisanaFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Fondazione C.N.R...RecruitingEnd Stage Liver DIseaseItaly
-
Charite University, Berlin, GermanyRecruitingLiver Transplant Disorder | Hepatocellular InjuryGermany
-
Matteo RavaioliCompletedLiver Diseases | Kidney DiseasesItaly
-
University Hospital, AachenCompletedLiver Transplant | Hepatocellular InjuryGermany, Czechia
-
Organ Recovery Systems, Inc.Completed
-
University Medical Center GroningenUniversity of ZurichCompletedLiver Transplantation | Organ Preservation | Hypothermic Machine PerfusionSwitzerland, Netherlands
-
Bridge to Life Ltd.Active, not recruitingLiver Failure | End Stage Liver DIseaseUnited States
-
Medical University of WarsawNational Science Centre, PolandRecruitingLiver Cirrhosis | Liver Tumor | Liver Transplant Failure and RejectionPoland
-
Hospices Civils de LyonCompletedLiver TransplantationFrance
-
UMC UtrechtCompletedHypoplastic Left Heart Syndrome | Aortic Coarctation | Congenital Heart DefectsNetherlands